These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

568 related items for PubMed ID: 14722738

  • 1. Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening.
    Alebouyeh M, Moussavi F, Haddad-Deylami H, Vossough P.
    Ann Hematol; 2004 Jul; 83(7):430-3. PubMed ID: 14722738
    [Abstract] [Full Text] [Related]

  • 2. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.
    Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.
    Haematologica; 2004 Oct; 89(10):1172-8. PubMed ID: 15477200
    [Abstract] [Full Text] [Related]

  • 3. Response to hydroxyurea therapy in beta-thalassemia.
    Koren A, Levin C, Dgany O, Kransnov T, Elhasid R, Zalman L, Palmor H, Tamary H.
    Am J Hematol; 2008 May; 83(5):366-70. PubMed ID: 18181203
    [Abstract] [Full Text] [Related]

  • 4. Hematologic response to hydroxyurea therapy in children with beta-thalassemia major.
    Mtvarelidze Z, Kvezereli-Kopadze A, Kvezereli-Kopadze M, Mestiashvili I.
    Georgian Med News; 2008 Mar; (156):91-4. PubMed ID: 18403819
    [Abstract] [Full Text] [Related]

  • 5. Hydroxyurea in thalassemia intermedia--a promising therapy.
    Dixit A, Chatterjee TC, Mishra P, Choudhry DR, Mahapatra M, Tyagi S, Kabra M, Saxena R, Choudhry VP.
    Ann Hematol; 2005 Jul; 84(7):441-6. PubMed ID: 15838670
    [Abstract] [Full Text] [Related]

  • 6. Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study.
    Italia KY, Jijina FF, Merchant R, Panjwani S, Nadkarni AH, Sawant PM, Nair SB, Ghosh K, Colah RB.
    J Clin Pathol; 2010 Feb; 63(2):147-50. PubMed ID: 20154037
    [Abstract] [Full Text] [Related]

  • 7. Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature.
    Ehsani MA, Hedayati-Asl AA, Bagheri A, Zeinali S, Rashidi A.
    Pediatr Hematol Oncol; 2009 Nov; 26(8):560-5. PubMed ID: 19954365
    [Abstract] [Full Text] [Related]

  • 8. Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India.
    Italia KY, Jijina FJ, Merchant R, Panjwani S, Nadkarni AH, Sawant PM, Nair SB, Ghosh K, Colah RB.
    Clin Chim Acta; 2009 Sep; 407(1-2):10-5. PubMed ID: 19545554
    [Abstract] [Full Text] [Related]

  • 9. Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia.
    Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.
    Transfusion; 2007 Oct; 47(10):1830-6. PubMed ID: 17880608
    [Abstract] [Full Text] [Related]

  • 10. Response to hydroxycarbamide in pediatric β-thalassemia intermedia: 8 years' follow-up in Egypt.
    El-Beshlawy A, El-Ghamrawy M, EL-Ela MA, Said F, Adolf S, Abdel-Razek AR, Magdy RI, Abdel-Salam A.
    Ann Hematol; 2014 Dec; 93(12):2045-50. PubMed ID: 25062719
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT).
    Ansari SH, Shamsi TS, Siddiqui FJ, Irfan M, Perveen K, Farzana T, Panjwani VK, Yousuf A, Mehboob T.
    J Pediatr Hematol Oncol; 2007 Nov; 29(11):743-6. PubMed ID: 17984691
    [Abstract] [Full Text] [Related]

  • 12. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.
    Rogers ZR.
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):42-7. PubMed ID: 9317200
    [Abstract] [Full Text] [Related]

  • 13. Treatment of beta-thalassemia with hydroxyurea (HU)--effects of HU on globin gene expression.
    Huang SZ, Ren ZR, Chen MJ, Xu HP, Zeng YT, Rodgers GP, Zeng FY, Schechter AN.
    Sci China B; 1994 Nov; 37(11):1350-9. PubMed ID: 7865126
    [Abstract] [Full Text] [Related]

  • 14. Report on patients with non transfusion-dependent β-thalassemia major being treated with hydroxyurea attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013.
    Kosaryan M, Karami H, Zafari M, Yaghobi N.
    Hemoglobin; 2014 Nov; 38(2):115-8. PubMed ID: 24471558
    [Abstract] [Full Text] [Related]

  • 15. The activity of superoxide dismutase in hydroxyurea-treated E beta thalassemia.
    Ajanta H, Chakraborty S, Madhusnata D, Bhattacharya DK, Manisha D.
    J Assoc Physicians India; 2002 Aug; 50():1034-5. PubMed ID: 12421025
    [Abstract] [Full Text] [Related]

  • 16. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia.
    Karimi M, Mohammadi F, Behmanesh F, Samani SM, Borzouee M, Amoozgar H, Haghpanah S.
    Eur J Haematol; 2010 Jan 01; 84(1):52-8. PubMed ID: 19799627
    [Abstract] [Full Text] [Related]

  • 17. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
    Italia K, Jain D, Gattani S, Jijina F, Nadkarni A, Sawant P, Nair S, Mohanty D, Ghosh K, Colah R.
    Blood Cells Mol Dis; 2009 Jan 01; 42(1):25-31. PubMed ID: 18954999
    [Abstract] [Full Text] [Related]

  • 18. Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease.
    Triadou P, Maier-Redelsperger M, Krishnamoorty R, Deschamps A, Casadevall N, Dunda O, Ducrocq R, Elion J, Girot R, Labie D.
    Nouv Rev Fr Hematol (1978); 1994 Oct 01; 36(5):367-72. PubMed ID: 7534399
    [Abstract] [Full Text] [Related]

  • 19. The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian β-thalassemia patients.
    Banan M, Bayat H, Azarkeivan A, Mohammadparast S, Kamali K, Farashi S, Bayat N, Khani MH, Neishabury M, Najmabadi H.
    Hemoglobin; 2012 Oct 01; 36(4):371-80. PubMed ID: 22686296
    [Abstract] [Full Text] [Related]

  • 20. Treatment with hydroxyurea in thalassemia intermedia with paravertebral pseudotumors of extramedullary hematopoiesis.
    Cario H, Wegener M, Debatin KM, Kohne E.
    Ann Hematol; 2002 Aug 01; 81(8):478-82. PubMed ID: 12224008
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.